Bioequivalence Study of Palbociclib Tablets in Healthy Volunteers
Authors:
Open Access
- 1 August 2025
- journal article
- clinical trial-report
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 7111-7121
Abstract
Objective: Bioequivalence of palbociclib tablets was evaluated in healthy volunteers under fasting and fed conditions in this study. Methods: This bioequivalence trial, which randomized subjects to receive palbociclib under fed or fasted conditions, generated these results. High-performance liquid chromatography-mass spectrometry (HPLC-MS) was employed to determine palbociclib concentrations in plasma from collected blood samples. Pharmacokinetic (PK) parameters were calculated using the non-compartmental analysis (NCA) module within Phoenix WinNonlin version 8.2. Statistical analysis of key pharmacokinetic parameters-maximum plasma concentration (Cmax), area under the concentration-time curve from zero to last quantifiable time (AUC0-t), and area under the curve from zero to infinity (AUC0–∞)-was conducted using the bioequivalence (BE) module within WinNonLin. A total of 68 healthy subjects were enrolled and randomized to either a fasted or a fed group. All subjects were randomized into T-R and R-T sequences (T: test formulation; R: reference formulation). Results: The geometric mean ratios (T/R) of Cmax, AUC0-t and AUC0–∞ of palbociclib in plasma were 97.96%, 96.16%, and 96.02% under fasting conditions; The geometric mean ratios (T/R) of Cmax, AUC0-t and AUC0-∞ of palbociclib in plasma were 95.47%, 96.49%, and 96.36% under fed conditions. All 90% confidence intervals for the geometric mean ratios were contained entirely within the range of 80.00% to 125.00%. Under the fasted and fed conditions, the test preparation and the reference preparation of palbociclib tablets were bioequivalent. Adverse events (AEs) occurred at similar rates in the fasted and fed groups. Conclusion: The result indicated that the test preparation and the reference preparation of palbociclib tablets were bioequivalent under the fasted and fed conditions. The safety of the two preparations was good. Clinical Trial Registration: This trial was registered on the Chinese Clinical Trial website (http://www.chinadrugtrials.org.cn/index.html # CTR20220977).Keywords
This publication has 9 references indexed in Scilit:
- Bioequivalence Study of Palbociclib Capsules in Healthy Chinese Subjects Under Fasting and Fed ConditionsClinical Drug Investigation, 2021
- Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysisClinical Drug Investigation, 2021
- Cancer-Associated Adipocytes in Breast Cancer: Causes and ConsequencesInternational Journal of Molecular Sciences, 2021
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast CancerClinical Cancer Research, 2019
- Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerJNCI: Journal of the National Cancer Institute, 2018
- Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approvalBreast Cancer Research, 2018
- Effect of food on the bioavailability of palbociclibCancer Chemotherapy and Pharmacology, 2017
- Palbociclib: First Global ApprovalDrugs, 2015